18th Annual Q-Bio Conference: Global scholars explore new Frontiers in quantitative biology
Meeting Announcement
- Core themes including space geology and nuclear energy have emerged
- Introduction of Emile Argand Award winner and plenary speakers from IUGS
- Operation of the GeoFilm Festival for public engagement, targeting youth and those with a general interest in geology
- The Closing Ceremony’s 'Busan Declaration' to highlight geologists’role and responsibility in addressing environmental challenges & climate change
The world's leading cardiology experts will convene at ESC Congress 2024 in London this summer.
12 Hot Line sessions will be held in the Main Auditorium, where eagerly awaited findings from recently completed clinical trials will be presented for the first time.
These presentations have the potential to change the way that patients are treated in clinical practice in the future.
The World Mitochondria Society (WMS) and the International Society of Microbiota (ISM) are proud to announce the First World Conference on Targeting Extracellular Vesicles (EVs), scheduled for October 17-18, 2024, at the Corinthia Palace, Malta. This event will explore the latest advancements in extracellular vesicle research and their transformative applications in health and therapeutics, with a special focus on the interactions between EVs, mitochondria, and microbiota.
EVs are gaining immense traction as a pivotal element in the evolution of next-generation therapeutic strategies. EVs, functioning as fundamental mediators of intercellular communication, exhibit remarkable potential in revolutionizing the treatment paradigms for a myriad of diseases. This conference aims to underscore the strategic importance of EVs, showcasing their capabilities in targeted drug delivery, regenerative medicine, and immune modulation. By integrating EV research with advanced technologies, scientists are on the cusp of developing innovative therapeutic approaches to tackle complex conditions such as neurodegeneration, cancer, and metabolic disorders. The strategic emphasis on EVs promises to enhance the precision and effectiveness of personalized treatments, significantly improving patient outcomes across a broad spectrum of diseases.
From July 30-31, Alex Zhavoronkov, PhD, founder and co-CEO of clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine will be attending SCRI Clinical Trials Symposium 2024 at Raffles City Convention Centre, and Brainstorm AI 2024: The New Race for AI at The Ritz-Carlton, Millenia Singapore, sharing strategic insights with global leaders across the technology and healthcare industries.